<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000484435"><TermName>dasatinib</TermName><TermPronunciation>(da-SA-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. Dasatinib is also being studied in the treatment of certain other blood diseases and types of cancer. Dasatinib binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor. Also called BMS-354825 and Sprycel.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000716719" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;dasatinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000716718" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;dasatinib&quot;" language="es" id="_4"/><SpanishTermName>dasatinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento usado para tratar ciertos tipos de leucemia mieloide aguda y leucemia linfoblástica aguda. El dasatinib también está en estudio para tratar otras enfermedades de la sangre y tipos de cáncer. El dasatinib se une al BCR-ABL y otras proteínas que ayudan a crecer a las células cancerosas, y las bloquea. Es un tipo de inhibidor de la tirosina cinasa. También se llama BMS-354825 y Sprycel.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-09-15</DateFirstPublished><DateLastModified>2007-06-06</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000495782">Dasatinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
